This article is more than 5 years old. Information may no longer be current.

Bausch + Lomb initiates OVD clinical trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Bausch + Lomb has initiated a clinical trial of a new ophthalmic viscosurgical device, the company announced in a press release.

The OVD is intended to provide a novel formulation to meet a cataract surgeon’s needs, the release said. The company plans to file for premarket approval with the FDA at the end of the trial and bring the product to market in the U.S. in 2019.

“OVDs play a critical role in ophthalmic surgery, and selection is highly individualized based on clinical surgical requirements and the surgeon’s preferences,” Chuck Hess, vice president and general manager of U.S. Surgical at Bausch + Lomb, said in the release. “Our goal is to provide surgeons with a new option as part of our commitment to delivering innovations that expand their cataract surgery armamentarium.”